- Home
- CTO vs GOSS Comparison
CTO vs GOSS Comparison
Compare CTO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- GOSS
- Stock Information
- Founded
- CTO 1902
- GOSS 2015
- Country
- CTO United States
- GOSS United States
- Employees
- CTO N/A
- GOSS N/A
- Industry
- CTO Real Estate Investment Trusts
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- GOSS Health Care
- Exchange
- CTO Nasdaq
- GOSS Nasdaq
- Market Cap
- CTO 569.2M
- GOSS 586.6M
- IPO Year
- CTO N/A
- GOSS 2019
- Fundamental
- Price
- CTO $16.47
- GOSS $3.08
- Analyst Decision
- CTO Strong Buy
- GOSS Strong Buy
- Analyst Count
- CTO 3
- GOSS 6
- Target Price
- CTO $22.00
- GOSS $8.60
- AVG Volume (30 Days)
- CTO 254.9K
- GOSS 4.8M
- Earning Date
- CTO 10-23-2025
- GOSS 11-06-2025
- Dividend Yield
- CTO 9.25%
- GOSS N/A
- EPS Growth
- CTO N/A
- GOSS N/A
- EPS
- CTO N/A
- GOSS N/A
- Revenue
- CTO $140,996,000.00
- GOSS $40,237,000.00
- Revenue This Year
- CTO $21.41
- GOSS N/A
- Revenue Next Year
- CTO $8.49
- GOSS $34.10
- P/E Ratio
- CTO N/A
- GOSS N/A
- Revenue Growth
- CTO 22.26
- GOSS N/A
- 52 Week Low
- CTO $16.12
- GOSS $0.66
- 52 Week High
- CTO $20.88
- GOSS $3.60
- Technical
- Relative Strength Index (RSI)
- CTO 40.44
- GOSS 61.72
- Support Level
- CTO $16.32
- GOSS $2.93
- Resistance Level
- CTO $16.73
- GOSS $3.37
- Average True Range (ATR)
- CTO 0.26
- GOSS 0.29
- MACD
- CTO -0.07
- GOSS 0.01
- Stochastic Oscillator
- CTO 12.00
- GOSS 57.55
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.